TYRA: SEC Form S-3ASR filed by Tyra Biosciences Inc.
Stocks in this Quantisnow insightHealth Care
Historical context for TYRA
Across the 18 sessions after earlier TYRA headlines, the stock closed higher 9 times and lower 9 times, with a median move of 2.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TYRA | SPY |
|---|---|---|---|
| Sep 9, 2026 | Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratiniband 1 other headline that session | -17.7% | -0.5% |
| Sep 4, 2026 | Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 | +15.2% | -0.4% |
| Aug 5, 2026 | Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights | -21.0% | -0.2% |
| May 21, 2026 | TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY | -1.1% | +0.2% |
| May 19, 2026 | Wolfe Research initiated coverage on Tyra Biosciences | -5.3% | -0.7% |
| May 13, 2026 | Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights | +3.8% | +0.6% |
Quantisnow market dataNASDAQ
TYRA
Tyra Biosciences Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for TYRA
Full TYRA profile on Quantisnow Follow TYRA and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time